Open-mkt buys · 90d
—
0 trades · 0 insiders
Open-mkt sales · 90d
$3.81M
19 trades · 5 insiders
Net · 90d
$-3.81M
Insiders on file
31
Daily buy vs sell · 90 days
■ Open-market buys (P) ■ Open-market sales (S) · daily dollar value by transaction date
Insiders
| Insider | Role | Trades | Bought | Sold | Last trade |
|---|---|---|---|---|---|
| CAREY STEPHEN P. | Vice President and CFO | 75 | $0 | $9.48M | 2026-10-29 |
| Lalwani Nikhil | PRESIDENT & CEO, Director | 51 | $200.0K | $21.14M | 2026-10-15 |
| Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | 57 | $0 | $1.02M | 2026-10-13 |
| Thoma Jeanne | Director | 13 | $49.8K | $2.06M | 2026-09-11 |
| Gosebruch Henry O | Director | 2 | $0 | $0 | 2026-08-19 |
| Gutwerg Ori | SVP, GENERICS | 42 | $0 | $2.92M | 2026-08-10 |
| HAUGHEY THOMAS | Director | 17 | $497.2K | $1.82M | 2026-06-08 |
| Leonard Matthew J | Director | 6 | $0 | $840.7K | 2026-05-21 |
| Pera Antonio R | Director | 13 | $126.8K | $1.82M | 2026-05-21 |
| TANNENBAUM RENEE P | Director | 7 | $0 | $273.8K | 2026-05-21 |
| Walsh Patrick D | Interim President and CEO | 23 | $708.0K | $3.12M | 2026-05-13 |
| Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | 13 | $0 | $820.2K | 2026-05-12 |
| Mutz Christopher | HEAD OF RARE DISEASE | 38 | $0 | $2.86M | 2026-03-13 |
| Davis Krista | SVP, CHIEF HR OFFICER | 30 | $0 | $1.62M | 2026-03-09 |
| Gassert Chad | SVP - CORP. DEV. & STRATEGY | 28 | $275.1K | $15.14M | 2026-02-28 |
| Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | 80 | $276.5K | $63.25M | 2026-02-26 |
| Marken James G. | Vice President, Operations | 78 | $0 | $5.09M | 2024-06-07 |
| MERIDIAN VENTURE PARTNERS II LP | 10% Owner | 10 | $0 | $37.87M | 2023-08-16 |
| NASH DAVID | Director | 9 | $99.4K | $0 | 2023-05-23 |
| Meridian Venture Partners II GP, L.P. | 10% Owner | 7 | $0 | $10.28M | 2022-12-01 |
| Brown Robert E. JR | Director, 10% Owner | 33 | $0 | $8.32M | 2022-04-27 |
| Schrepfer Robert W | VP Bus Dev & Con Mfg | 58 | $0 | $3.54M | 2021-03-29 |
| PRZYBYL ARTHUR | President and CEO | 125 | $128.9K | $15.03M | 2020-04-07 |
| Penn Thomas A. | Director, 10% Owner | 12 | $0 | $0 | 2019-03-28 |
| MARSHBANKS TRACY | Director | 36 | $0 | $27.30M | 2018-05-16 |
| HOLUBOW FRED | Director | 11 | $0 | $0 | 2018-03-20 |
| RAYNOR DANIEL | Director | 19 | $0 | $16.63M | 2018-03-19 |
| Arnold Charlotte C. | Vice President and CFO | 69 | $0 | $2.83M | 2016-04-07 |
| LANKAU PETER A | Director | 4 | $0 | $0 | 2016-04-07 |
| MANGANO ROSS J | Director | 7 | $319.4K | $0 | 2014-09-15 |
| Jamnick Robert J. | VP, Quality & Product Develop. | 1 | $0 | $0 | 2014-04-01 |
Trade history
| Insider | Role | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|---|
| CAREY STEPHEN P. | SVP & CFO | S Sale | 2026-10-29 | 2026-10-30 | 2,850 | $72.87 | $207.7K | 166,143 | SEC↗ |
| Lalwani Nikhil | PRESIDENT & CEO, Director | S Sale | 2026-10-15 | 2026-10-16 | 5,400 | $71.89 | $388.2K | 333,689 | SEC↗ |
| Cook Meredith | SR. VP, GENERAL COUNSEL & SE | S Sale | 2026-10-13 | 2026-10-13 | 500 | $73.59 | $36.8K | 73,424 | SEC↗ |
| CAREY STEPHEN P. | SVP & CFO | S Sale | 2026-09-29 | 2026-09-30 | 2,850 | $73.00 | $208.1K | 168,993 | SEC↗ |
| CAREY STEPHEN P. | SVP & CFO | S Sale | 2026-09-29 | 2026-09-30 | 2,850 | $73.00 | $208.1K | 168,993 | SEC↗ |
| Lalwani Nikhil | PRESIDENT & CEO | S Sale | 2026-09-15 | 2026-09-16 | 5,400 | $71.00 | $383.4K | 339,089 | SEC↗ |
| Lalwani Nikhil | PRESIDENT & CEO, Director | S Sale | 2026-09-15 | 2026-09-16 | 5,400 | $71.00 | $383.4K | 339,089 | SEC↗ |
| Cook Meredith | SR. VP, GENERAL COUNSEL & SE | S Sale | 2026-09-14 | 2026-09-14 | 500 | $70.79 | $35.4K | 73,924 | SEC↗ |
| Cook Meredith | SR. VP, GENERAL COUNSEL & SE | S Sale | 2026-09-14 | 2026-09-14 | 500 | $70.79 | $35.4K | 73,924 | SEC↗ |
| Thoma Jeanne | Director | S Sale | 2026-09-11 | 2026-09-14 | 1,000 | $71.53 | $71.5K | 26,762 | SEC↗ |
| Thoma Jeanne | Director | S Sale | 2026-09-11 | 2026-09-14 | 1,000 | $71.53 | $71.5K | 26,762 | SEC↗ |
| CAREY STEPHEN P. | SVP & CFO | S Sale | 2026-08-31 | 2026-09-01 | 2,850 | $72.80 | $207.5K | 171,843 | SEC↗ |
| CAREY STEPHEN P. | SVP & CFO | S Sale | 2026-08-31 | 2026-09-01 | 2,850 | $72.80 | $207.5K | 171,843 | SEC↗ |
| Lalwani Nikhil | PRESIDENT & CEO | S Sale | 2026-08-25 | 2026-08-26 | 5,400 | $74.30 | $401.2K | 344,489 | SEC↗ |
| Lalwani Nikhil | PRESIDENT & CEO, Director | S Sale | 2026-08-25 | 2026-08-26 | 5,400 | $74.30 | $401.2K | 344,489 | SEC↗ |
| Gosebruch Henry O | Director | A Award | 2026-08-19 | 2026-08-27 | 6,662 | — | $0 | 6,662 | SEC↗ |
| Gosebruch Henry O | Director | A Award | 2026-08-19 | 2026-08-27 | 6,662 | — | $0 | 6,662 | SEC↗ |
| Cook Meredith | SR. VP, GENERAL COUNSEL & SE | S Sale | 2026-08-13 | 2026-08-13 | 500 | $75.48 | $37.7K | 74,424 | SEC↗ |
| Cook Meredith | SR. VP, GENERAL COUNSEL & SE | S Sale | 2026-08-13 | 2026-08-13 | 500 | $75.48 | $37.7K | 74,424 | SEC↗ |
| Gutwerg Ori | SVP, GENERICS | S Sale | 2026-08-10 | 2026-08-11 | 3,162 | $77.00 | $243.5K | 75,534 | SEC↗ |
| Gutwerg Ori | SVP, GENERICS | S Sale | 2026-08-10 | 2026-08-11 | 3,162 | $77.00 | $243.5K | 75,534 | SEC↗ |
| CAREY STEPHEN P. | SVP & CFO | S Sale | 2026-07-29 | 2026-07-30 | 2,850 | $81.36 | $231.9K | 174,693 | SEC↗ |
| CAREY STEPHEN P. | SVP & CFO | S Sale | 2026-07-29 | 2026-07-30 | 2,850 | $81.36 | $231.9K | 174,693 | SEC↗ |
| Cook Meredith | SR. VP, GENERAL COUNSEL & SE | F Tax w/h | 2026-07-18 | 2026-07-21 | 2,466 | $79.20 | $195.3K | 74,924 | SEC↗ |
| Cook Meredith | SR. VP, GENERAL COUNSEL & SE | S Sale | 2026-07-13 | 2026-07-14 | 500 | $81.84 | $40.9K | 77,390 | SEC↗ |
| CAREY STEPHEN P. | SVP & CFO | M Exercise deriv | 2026-07-02 | 2026-07-06 | 3,313 | $49.51 | $164.0K | 3,313 | SEC↗ |
| CAREY STEPHEN P. | SVP & CFO | S Sale | 2026-07-02 | 2026-07-06 | 3,313 | $86.00 | $284.9K | 177,543 | SEC↗ |
| CAREY STEPHEN P. | SVP & CFO | M Exercise | 2026-07-02 | 2026-07-06 | 3,313 | $49.51 | $164.0K | 180,856 | SEC↗ |
| CAREY STEPHEN P. | SVP & CFO | S Sale | 2026-06-29 | 2026-06-30 | 2,850 | $84.12 | $239.7K | 177,543 | SEC↗ |
| Cook Meredith | SR. VP, GENERAL COUNSEL & SE | S Sale | 2026-06-12 | 2026-06-15 | 500 | $82.03 | $41.0K | 77,890 | SEC↗ |
| HAUGHEY THOMAS | Director | S Sale | 2026-06-08 | 2026-06-10 | 2,000 | $80.88 | $161.8K | 38,878 | SEC↗ |
| CAREY STEPHEN P. | SVP & CFO | M Exercise deriv | 2026-06-05 | 2026-06-09 | 3,312 | $49.51 | $164.0K | 6,626 | SEC↗ |
| CAREY STEPHEN P. | SVP & CFO | M Exercise | 2026-06-05 | 2026-06-09 | 3,312 | $49.51 | $164.0K | 183,705 | SEC↗ |
| CAREY STEPHEN P. | SVP & CFO | S Sale | 2026-06-05 | 2026-06-09 | 3,312 | $80.00 | $265.0K | 180,393 | SEC↗ |
| HAUGHEY THOMAS | Director | A Award | 2026-05-21 | 2026-06-10 | 4,357 | — | $0 | 40,878 | SEC↗ |
| Leonard Matthew J | Director | A Award | 2026-05-21 | 2026-06-10 | 4,357 | — | $0 | 11,221 | SEC↗ |
| Pera Antonio R | Director | A Award | 2026-05-21 | 2026-06-10 | 4,357 | — | $0 | 27,017 | SEC↗ |
| TANNENBAUM RENEE P | Director | A Award | 2026-05-21 | 2026-06-10 | 4,357 | — | $0 | 29,514 | SEC↗ |
| Thoma Jeanne | Director | A Award | 2026-05-21 | 2026-06-10 | 4,357 | — | $0 | 27,762 | SEC↗ |
| Cook Meredith | SR. VP, GENERAL COUNSEL & SE | S Sale | 2026-05-13 | 2026-05-13 | 500 | $78.16 | $39.1K | 78,390 | SEC↗ |
| Walsh Patrick D | Director | S Sale | 2026-05-13 | 2026-05-13 | 10,000 | $80.63 | $806.3K | 38,432 | SEC↗ |
| Gutwerg Ori | SVP, GENERICS | S Sale | 2026-05-12 | 2026-05-13 | 2,772 | $79.50 | $220.4K | 78,696 | SEC↗ |
| Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRAN | S Sale | 2026-05-12 | 2026-05-13 | 459 | $79.21 | $36.4K | 38,271 | SEC↗ |
| Lalwani Nikhil | PRESIDENT & CEO | S Sale | 2026-05-11 | 2026-05-13 | 55,000 | $77.57 | $4.27M | 349,889 | SEC↗ |
| Walsh Patrick D | Director | S Sale | 2026-05-11 | 2026-05-13 | 3,973 | $80.75 | $320.8K | 48,432 | SEC↗ |
| Cook Meredith | SR. VP, GENERAL COUNSEL & SE | S Sale | 2026-04-13 | 2026-04-13 | 500 | $77.95 | $39.0K | 78,890 | SEC↗ |
| Cook Meredith | SR. VP, GENERAL COUNSEL & SE | S Sale | 2026-03-13 | 2026-03-13 | 500 | $72.62 | $36.3K | 79,390 | SEC↗ |
| Mutz Christopher | HEAD OF RARE DISEASE | S Sale | 2026-03-13 | 2026-03-13 | 3,162 | $71.64 | $226.5K | 91,309 | SEC↗ |
| Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRAN | S Sale | 2026-03-11 | 2026-03-13 | 4,772 | $74.91 | $357.5K | 38,730 | SEC↗ |
| Davis Krista | SVP, CHIEF HR OFFICER | S Sale | 2026-03-09 | 2026-03-10 | 5,087 | $74.13 | $377.1K | 51,946 | SEC↗ |
| Mutz Christopher | HEAD OF RARE DISEASE | S Sale | 2026-03-09 | 2026-03-10 | 3,602 | $74.18 | $267.2K | 94,471 | SEC↗ |
| CAREY STEPHEN P. | SVP & CFO | F Tax w/h | 2026-03-07 | 2026-03-10 | 5,150 | $74.04 | $381.3K | 180,393 | SEC↗ |
| Gutwerg Ori | SVP, GENERICS | F Tax w/h | 2026-03-07 | 2026-03-10 | 3,314 | $74.04 | $245.4K | 81,468 | SEC↗ |
| Lalwani Nikhil | PRESIDENT & CEO | F Tax w/h | 2026-03-07 | 2026-03-10 | 17,060 | $74.04 | $1.26M | 404,889 | SEC↗ |
| Mutz Christopher | HEAD OF RARE DISEASE | F Tax w/h | 2026-03-07 | 2026-03-10 | 3,314 | $74.04 | $245.4K | 98,073 | SEC↗ |
| Davis Krista | SVP, CHIEF HR OFFICER | S Sale | 2026-03-06 | 2026-03-10 | 1,485 | $75.00 | $111.4K | 57,033 | SEC↗ |
| Mutz Christopher | HEAD OF RARE DISEASE | S Sale | 2026-03-06 | 2026-03-10 | 2,121 | $74.22 | $157.4K | 101,387 | SEC↗ |
| CAREY STEPHEN P. | SVP & CFO | M Exercise deriv | 2026-03-05 | 2026-03-05 | 3,312 | $49.51 | $164.0K | 9,938 | SEC↗ |
| CAREY STEPHEN P. | SVP & CFO | S Sale | 2026-03-05 | 2026-03-05 | 3,312 | $75.42 | $249.8K | 189,543 | SEC↗ |
| CAREY STEPHEN P. | SVP & CFO | M Exercise | 2026-03-05 | 2026-03-05 | 3,312 | $49.51 | $164.0K | 192,855 | SEC↗ |
| CAREY STEPHEN P. | SVP & CFO | S Sale | 2026-03-05 | 2026-03-05 | 4,000 | $75.56 | $302.2K | 185,543 | SEC↗ |
| Walsh Patrick D | Director | S Sale | 2026-03-03 | 2026-03-03 | 6,000 | $74.23 | $445.4K | 52,405 | SEC↗ |
| Gutwerg Ori | SVP, GENERICS | S Sale | 2026-03-03 | 2026-03-04 | 2,060 | $76.50 | $157.6K | 84,782 | SEC↗ |
| Mutz Christopher | HEAD OF RARE DISEASE | S Sale | 2026-03-02 | 2026-03-04 | 417 | $74.00 | $30.9K | 103,508 | SEC↗ |
| CAREY STEPHEN P. | SVP & CFO | F Tax w/h | 2026-02-28 | 2026-03-02 | 2,773 | $73.90 | $204.9K | 189,543 | SEC↗ |
| Cook Meredith | SR. VP, GENERAL COUNSEL & SE | F Tax w/h | 2026-02-28 | 2026-03-02 | 1,555 | $73.90 | $114.9K | 79,890 | SEC↗ |
| Davis Krista | SVP, CHIEF HR OFFICER | F Tax w/h | 2026-02-28 | 2026-03-02 | 1,555 | $73.90 | $114.9K | 58,518 | SEC↗ |
| Gassert Chad | SVP - CORP. DEV. & STRATEGY | F Tax w/h | 2026-02-28 | 2026-03-02 | 2,221 | $73.90 | $164.1K | 74,916 | SEC↗ |
| Gutwerg Ori | SVP, GENERICS | F Tax w/h | 2026-02-28 | 2026-03-02 | 2,221 | $73.90 | $164.1K | 86,842 | SEC↗ |
| Lalwani Nikhil | PRESIDENT & CEO | F Tax w/h | 2026-02-28 | 2026-03-02 | 12,217 | $73.90 | $902.8K | 421,949 | SEC↗ |
| Mutz Christopher | HEAD OF RARE DISEASE | F Tax w/h | 2026-02-28 | 2026-03-02 | 2,221 | $73.90 | $164.1K | 103,925 | SEC↗ |
| Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRAN | F Tax w/h | 2026-02-28 | 2026-03-02 | 628 | $73.90 | $46.4K | 43,502 | SEC↗ |
| CAREY STEPHEN P. | SVP & CFO | A Award | 2026-02-26 | 2026-03-02 | 22,233 | $77.15 | $1.72M | 192,316 | SEC↗ |
| Cook Meredith | SR. VP, GENERAL COUNSEL & SE | A Award | 2026-02-26 | 2026-03-02 | 13,895 | $77.15 | $1.07M | 81,445 | SEC↗ |
| Davis Krista | SVP, CHIEF HR OFFICER | A Award | 2026-02-26 | 2026-03-02 | 10,810 | $77.15 | $834.0K | 60,073 | SEC↗ |
| Gassert Chad | SVP - CORP. DEV. & STRATEGY | A Award | 2026-02-26 | 2026-03-02 | 11,116 | $77.15 | $857.6K | 77,137 | SEC↗ |
| Gutwerg Ori | SVP, GENERICS | A Award | 2026-02-26 | 2026-03-02 | 12,969 | $77.15 | $1.00M | 89,063 | SEC↗ |
| Lalwani Nikhil | PRESIDENT & CEO | A Award | 2026-02-26 | 2026-03-02 | 75,592 | $77.15 | $5.83M | 434,166 | SEC↗ |
| Mutz Christopher | HEAD OF RARE DISEASE | A Award | 2026-02-26 | 2026-03-02 | 21,306 | $77.15 | $1.64M | 106,146 | SEC↗ |
| Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRAN | A Award | 2026-02-26 | 2026-03-02 | 6,021 | $77.15 | $464.5K | 44,130 | SEC↗ |
| Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OP | A Award | 2026-02-26 | 2026-03-02 | 11,116 | $77.15 | $857.6K | 101,056 | SEC↗ |
| Davis Krista | SVP, CHIEF HR OFFICER | S Sale | 2026-02-20 | 2026-02-23 | 1,730 | $77.99 | $134.9K | 49,263 | SEC↗ |
| Mutz Christopher | HEAD OF RARE DISEASE | S Sale | 2026-02-20 | 2026-02-23 | 5,323 | $78.02 | $415.3K | 84,840 | SEC↗ |
| Davis Krista | SVP, CHIEF HR OFFICER | S Sale | 2026-02-19 | 2026-02-23 | 2,084 | $77.53 | $161.6K | 50,993 | SEC↗ |
| CAREY STEPHEN P. | SVP & CFO | F Tax w/h | 2026-02-14 | 2026-02-17 | 2,448 | $77.36 | $189.4K | 170,083 | SEC↗ |
| Cook Meredith | SR. VP, GENERAL COUNSEL & SE | F Tax w/h | 2026-02-14 | 2026-02-17 | 1,779 | $77.36 | $137.6K | 67,550 | SEC↗ |
| Davis Krista | SVP, CHIEF HR OFFICER | F Tax w/h | 2026-02-14 | 2026-02-17 | 1,290 | $77.36 | $99.8K | 53,077 | SEC↗ |
| Gassert Chad | SVP - CORP. DEV. & STRATEGY | F Tax w/h | 2026-02-14 | 2026-02-17 | 1,717 | $77.36 | $132.8K | 66,021 | SEC↗ |
| Gutwerg Ori | SVP, GENERICS | F Tax w/h | 2026-02-14 | 2026-02-17 | 1,888 | $77.36 | $146.1K | 76,094 | SEC↗ |
| Lalwani Nikhil | PRESIDENT & CEO | F Tax w/h | 2026-02-14 | 2026-02-17 | 10,298 | $77.36 | $796.7K | 358,574 | SEC↗ |
| Mutz Christopher | HEAD OF RARE DISEASE | F Tax w/h | 2026-02-14 | 2026-02-17 | 2,403 | $77.36 | $185.9K | 90,163 | SEC↗ |
| Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRAN | F Tax w/h | 2026-02-14 | 2026-02-17 | 485 | $77.36 | $37.5K | 38,109 | SEC↗ |
| Cook Meredith | SR. VP, GENERAL COUNSEL & SE | S Sale | 2026-02-13 | 2026-02-17 | 500 | $76.80 | $38.4K | 69,329 | SEC↗ |
| CAREY STEPHEN P. | SVP & CFO | F Tax w/h | 2026-02-12 | 2026-02-17 | 2,829 | $76.70 | $217.0K | 172,531 | SEC↗ |
| Cook Meredith | SR. VP, GENERAL COUNSEL & SE | F Tax w/h | 2026-02-12 | 2026-02-17 | 1,534 | $76.70 | $117.7K | 69,829 | SEC↗ |
| Davis Krista | SVP, CHIEF HR OFFICER | F Tax w/h | 2026-02-12 | 2026-02-17 | 1,180 | $76.70 | $90.5K | 54,367 | SEC↗ |
| Gassert Chad | SVP - CORP. DEV. & STRATEGY | F Tax w/h | 2026-02-12 | 2026-02-17 | 1,608 | $76.70 | $123.3K | 67,738 | SEC↗ |
| Gutwerg Ori | SVP, GENERICS | F Tax w/h | 2026-02-12 | 2026-02-17 | 1,775 | $76.70 | $136.1K | 77,982 | SEC↗ |
| Lalwani Nikhil | PRESIDENT & CEO | F Tax w/h | 2026-02-12 | 2026-02-17 | 11,688 | $76.70 | $896.5K | 368,872 | SEC↗ |
| Mutz Christopher | HEAD OF RARE DISEASE | F Tax w/h | 2026-02-12 | 2026-02-17 | 3,173 | $76.70 | $243.4K | 99,598 | SEC↗ |
| Mutz Christopher | HEAD OF RARE DISEASE | S Sale | 2026-02-12 | 2026-02-17 | 7,032 | $76.55 | $538.3K | 92,566 | SEC↗ |
| Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRAN | F Tax w/h | 2026-02-12 | 2026-02-17 | 566 | $76.70 | $43.4K | 38,594 | SEC↗ |
| Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OP | F Tax w/h | 2026-02-11 | 2026-02-13 | 2,898 | $76.25 | $221.0K | 89,940 | SEC↗ |
| Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRAN | F Tax w/h | 2026-02-11 | 2026-02-13 | 1,762 | $76.25 | $134.4K | 39,160 | SEC↗ |
| Mutz Christopher | HEAD OF RARE DISEASE | F Tax w/h | 2026-02-11 | 2026-02-13 | 4,546 | $76.25 | $346.6K | 102,771 | SEC↗ |
| Lalwani Nikhil | PRESIDENT & CEO | F Tax w/h | 2026-02-11 | 2026-02-13 | 30,659 | $76.25 | $2.34M | 380,560 | SEC↗ |
| Gutwerg Ori | SVP, GENERICS | F Tax w/h | 2026-02-11 | 2026-02-13 | 4,267 | $76.25 | $325.4K | 79,757 | SEC↗ |
| Gassert Chad | SVP - CORP. DEV. & STRATEGY | F Tax w/h | 2026-02-11 | 2026-02-13 | 4,269 | $76.25 | $325.5K | 69,346 | SEC↗ |
| Davis Krista | SVP, CHIEF HR OFFICER | F Tax w/h | 2026-02-11 | 2026-02-13 | 3,017 | $76.25 | $230.0K | 55,547 | SEC↗ |
| Cook Meredith | SR. VP, GENERAL COUNSEL & SE | F Tax w/h | 2026-02-11 | 2026-02-13 | 3,011 | $76.25 | $229.6K | 71,363 | SEC↗ |
| CAREY STEPHEN P. | SVP & CFO | F Tax w/h | 2026-02-11 | 2026-02-13 | 5,503 | $76.25 | $419.6K | 175,360 | SEC↗ |
| Cook Meredith | SR. VP, GENERAL COUNSEL & SE | S Sale | 2026-01-13 | 2026-01-14 | 500 | $84.33 | $42.2K | 74,374 | SEC↗ |
| Davis Krista | SVP, CHIEF HR OFFICER | S Sale | 2025-12-18 | 2025-12-19 | 1,622 | $82.40 | $133.7K | 58,564 | SEC↗ |
| Cook Meredith | SR. VP, GENERAL COUNSEL & SE | S Sale | 2025-12-12 | 2025-12-12 | 400 | $82.32 | $32.9K | 74,874 | SEC↗ |
| TANNENBAUM RENEE P | Director | S Sale | 2025-12-05 | 2025-12-09 | 1,800 | $81.15 | $146.1K | 25,157 | SEC↗ |
| Cook Meredith | SR. VP, GENERAL COUNSEL & SE | S Sale | 2025-11-13 | 2025-11-14 | 400 | $87.27 | $34.9K | 75,274 | SEC↗ |
| Gassert Chad | SVP - CORP. DEV. & STRATEGY | S Sale | 2025-11-13 | 2025-11-14 | 94 | $88.00 | $8.3K | 158,490 | SEC↗ |
| Walsh Patrick D | Director | S Sale | 2025-11-13 | 2025-11-17 | 8,643 | $86.88 | $750.9K | 61,405 | SEC↗ |
| Walsh Patrick D | Director | G Gift | 2025-11-13 | 2025-11-17 | 3,000 | — | $0 | 58,405 | SEC↗ |
| Gassert Chad | SVP - CORP. DEV. & STRATEGY | S Sale | 2025-11-12 | 2025-11-14 | 14,642 | $89.07 | $1.30M | 158,584 | SEC↗ |
| Cook Meredith | SR. VP, GENERAL COUNSEL & SE | S Sale | 2025-10-13 | 2025-10-14 | 400 | $90.09 | $36.0K | 75,674 | SEC↗ |
| Davis Krista | SVP, CHIEF HR OFFICER | S Sale | 2025-09-19 | 2025-09-22 | 1,000 | $98.04 | $98.0K | 60,186 | SEC↗ |
| Cook Meredith | SR. VP, GENERAL COUNSEL & SE | S Sale | 2025-09-12 | 2025-09-15 | 400 | $98.42 | $39.4K | 76,074 | SEC↗ |
| Davis Krista | SVP, CHIEF HR OFFICER | F Tax w/h | 2025-09-12 | 2025-09-15 | 1,710 | $97.71 | $167.1K | 61,186 | SEC↗ |
| Pera Antonio R | Director | S Sale | 2025-09-03 | 2025-09-04 | 7,292 | $94.94 | $692.3K | 22,660 | SEC↗ |
| Leonard Matthew J | Director | S Sale | 2025-08-25 | 2025-08-26 | 2,528 | $90.62 | $229.1K | 6,864 | SEC↗ |
| Davis Krista | SVP, CHIEF HR OFFICER | S Sale | 2025-08-22 | 2025-08-25 | 1,763 | $91.10 | $160.6K | 62,896 | SEC↗ |
| Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OP | S Sale | 2025-08-21 | 2025-08-22 | 52,988 | $90.44 | $4.79M | 431,920 | SEC↗ |
| Pera Antonio R | Director | S Sale | 2025-08-20 | 2025-08-20 | 5,421 | $89.73 | $486.4K | 29,952 | SEC↗ |
| Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OP | S Sale | 2025-08-20 | 2025-08-22 | 47,012 | $90.27 | $4.24M | 484,908 | SEC↗ |
| Leonard Matthew J | Director | S Sale | 2025-08-18 | 2025-08-18 | 6,937 | $88.17 | $611.6K | 9,392 | SEC↗ |
| Thoma Jeanne | Director | S Sale | 2025-08-18 | 2025-08-20 | 14,675 | $88.87 | $1.30M | 23,405 | SEC↗ |
| Thoma Jeanne | Director | S Sale | 2025-08-18 | 2025-08-20 | 6,865 | $89.76 | $616.2K | 38,080 | SEC↗ |
| Gassert Chad | SVP - CORP. DEV. & STRATEGY | S Sale | 2025-08-15 | 2025-08-18 | 20,000 | $86.97 | $1.74M | 173,226 | SEC↗ |
| Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OP | S Sale | 2025-08-15 | 2025-08-18 | 52,990 | $87.15 | $4.62M | 531,920 | SEC↗ |
| Walsh Patrick D | Director | S Sale | 2025-08-15 | 2025-08-18 | 9,000 | $89.05 | $801.5K | 70,048 | SEC↗ |
| Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OP | S Sale | 2025-08-14 | 2025-08-18 | 47,010 | $89.48 | $4.21M | 584,910 | SEC↗ |
| Cook Meredith | SR. VP, GENERAL COUNSEL & SE | S Sale | 2025-08-13 | 2025-08-14 | 400 | $88.87 | $35.5K | 76,474 | SEC↗ |
| CAREY STEPHEN P. | SVP & CFO | M Exercise deriv | 2025-08-12 | 2025-08-14 | 50,000 | $46.49 | $2.32M | 0 | SEC↗ |
| HAUGHEY THOMAS | Director | S Sale | 2025-08-12 | 2025-08-14 | 19,341 | $85.93 | $1.66M | 36,521 | SEC↗ |
| CAREY STEPHEN P. | SVP & CFO | S Sale | 2025-08-12 | 2025-08-14 | 50,000 | $86.07 | $4.30M | 180,863 | SEC↗ |
| CAREY STEPHEN P. | SVP & CFO | M Exercise | 2025-08-12 | 2025-08-14 | 50,000 | $46.49 | $2.32M | 230,863 | SEC↗ |
| Gutwerg Ori | SVP, GENERICS | S Sale | 2025-08-12 | 2025-08-14 | 5,873 | $86.53 | $508.2K | 84,024 | SEC↗ |
| Lalwani Nikhil | PRESIDENT & CEO | S Sale | 2025-08-12 | 2025-08-14 | 56,960 | $85.93 | $4.89M | 411,219 | SEC↗ |
| Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRAN | S Sale | 2025-08-12 | 2025-08-14 | 4,975 | $85.71 | $426.4K | 40,794 | SEC↗ |
| Cook Meredith | SR. VP, GENERAL COUNSEL & SE | F Tax w/h | 2025-07-18 | 2025-07-21 | 2,071 | $66.30 | $137.3K | 76,874 | SEC↗ |
| Cook Meredith | SR. VP, GENERAL COUNSEL & SE | S Sale | 2025-07-14 | 2025-07-14 | 400 | $64.88 | $26.0K | 78,945 | SEC↗ |
| Cook Meredith | SR. VP, GENERAL COUNSEL & SE | S Sale | 2025-06-13 | 2025-06-16 | 400 | $61.37 | $24.5K | 79,345 | SEC↗ |
| Walsh Patrick D | Director | A Award | 2025-05-22 | 2025-05-27 | 4,336 | — | $0 | 79,048 | SEC↗ |
| Thoma Jeanne | Director | A Award | 2025-05-22 | 2025-05-27 | 4,336 | — | $0 | 44,945 | SEC↗ |
| TANNENBAUM RENEE P | Director | A Award | 2025-05-22 | 2025-05-27 | 4,336 | — | $0 | 26,957 | SEC↗ |
| Pera Antonio R | Director | A Award | 2025-05-22 | 2025-05-27 | 4,336 | — | $0 | 35,373 | SEC↗ |
| Leonard Matthew J | Director | A Award | 2025-05-22 | 2025-05-27 | 4,336 | — | $0 | 16,329 | SEC↗ |
| HAUGHEY THOMAS | Director | A Award | 2025-05-22 | 2025-05-27 | 4,336 | — | $0 | 55,862 | SEC↗ |
| Gutwerg Ori | SVP, GENERICS | S Sale | 2025-05-15 | 2025-05-16 | 881 | $60.07 | $52.9K | 89,897 | SEC↗ |
| Mutz Christopher | HEAD OF RARE DISEASE | S Sale | 2025-05-14 | 2025-05-15 | 4,000 | $60.45 | $241.8K | 107,317 | SEC↗ |
| Cook Meredith | SR. VP, GENERAL COUNSEL & SE | S Sale | 2025-05-13 | 2025-05-13 | 400 | $62.20 | $24.9K | 79,745 | SEC↗ |
| Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OP | S Sale | 2025-05-09 | 2025-05-13 | 700 | $76.83 | $53.8K | 631,920 | SEC↗ |
| Cook Meredith | SR. VP, GENERAL COUNSEL & SE | S Sale | 2025-04-14 | 2025-04-14 | 400 | $68.96 | $27.6K | 80,145 | SEC↗ |
| CAREY STEPHEN P. | SVP & CFO | F Tax w/h | 2025-03-23 | 2025-03-25 | 6,210 | $64.26 | $399.1K | 180,863 | SEC↗ |
| Lalwani Nikhil | PRESIDENT & CEO | F Tax w/h | 2025-03-23 | 2025-03-25 | 17,455 | $64.26 | $1.12M | 468,179 | SEC↗ |
| Davis Krista | SVP, CHIEF HR OFFICER | S Sale | 2025-03-19 | 2025-03-20 | 1,866 | $65.00 | $121.3K | 64,659 | SEC↗ |
| Cook Meredith | SR. VP, GENERAL COUNSEL & SE | S Sale | 2025-03-13 | 2025-03-14 | 400 | $63.33 | $25.3K | 80,545 | SEC↗ |
| Davis Krista | SVP, CHIEF HR OFFICER | S Sale | 2025-03-07 | 2025-03-10 | 1,000 | $60.86 | $60.9K | 66,525 | SEC↗ |
| CAREY STEPHEN P. | SVP & CFO | F Tax w/h | 2025-03-07 | 2025-03-14 | 5,150 | $60.62 | $312.2K | 187,073 | SEC↗ |
| Gutwerg Ori | SVP, GENERICS | F Tax w/h | 2025-03-07 | 2025-03-14 | 3,314 | $60.62 | $200.9K | 90,778 | SEC↗ |
| Lalwani Nikhil | PRESIDENT & CEO | F Tax w/h | 2025-03-07 | 2025-03-14 | 17,060 | $60.62 | $1.03M | 485,634 | SEC↗ |
| Mutz Christopher | HEAD OF RARE DISEASE | F Tax w/h | 2025-03-07 | 2025-03-14 | 2,874 | $60.62 | $174.2K | 111,317 | SEC↗ |
| Gutwerg Ori | SVP, GENERICS | M Exercise deriv | 2025-03-05 | 2025-03-07 | 300 | $31.49 | $9.4K | 13,204 | SEC↗ |
| Gutwerg Ori | SVP, GENERICS | S Sale | 2025-03-05 | 2025-03-07 | 300 | $60.03 | $18.0K | 99,176 | SEC↗ |
| Gutwerg Ori | SVP, GENERICS | S Sale | 2025-03-05 | 2025-03-07 | 5,084 | $60.00 | $305.0K | 94,092 | SEC↗ |
| Gutwerg Ori | SVP, GENERICS | M Exercise | 2025-03-05 | 2025-03-07 | 300 | $31.49 | $9.4K | 99,476 | SEC↗ |
| CAREY STEPHEN P. | SVP & CFO | F Tax w/h | 2025-02-28 | 2025-03-04 | 1,861 | $61.89 | $115.2K | 192,223 | SEC↗ |
| Cook Meredith | SR. VP, GENERAL COUNSEL & SE | F Tax w/h | 2025-02-28 | 2025-03-04 | 1,099 | $61.89 | $68.0K | 80,945 | SEC↗ |
| Davis Krista | SVP, CHIEF HR OFFICER | F Tax w/h | 2025-02-28 | 2025-03-04 | 1,099 | $61.89 | $68.0K | 67,525 | SEC↗ |
| Gutwerg Ori | SVP, GENERICS | F Tax w/h | 2025-02-28 | 2025-03-04 | 1,570 | $61.89 | $97.2K | 99,176 | SEC↗ |
| Lalwani Nikhil | PRESIDENT & CEO | F Tax w/h | 2025-02-28 | 2025-03-04 | 12,216 | $61.89 | $756.0K | 502,694 | SEC↗ |
| Mutz Christopher | HEAD OF RARE DISEASE | F Tax w/h | 2025-02-28 | 2025-03-04 | 1,275 | $61.89 | $78.9K | 114,191 | SEC↗ |
| Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRAN | F Tax w/h | 2025-02-28 | 2025-03-04 | 627 | $61.89 | $38.8K | 45,465 | SEC↗ |
| Davis Krista | SVP, CHIEF HR OFFICER | S Sale | 2025-02-21 | 2025-02-24 | 1,000 | $60.20 | $60.2K | 68,624 | SEC↗ |
| Gutwerg Ori | SVP, GENERICS | F Tax w/h | 2025-02-15 | 2025-02-18 | 1,167 | $58.92 | $68.8K | 100,746 | SEC↗ |
| Mutz Christopher | HEAD OF RARE DISEASE | F Tax w/h | 2025-02-15 | 2025-02-18 | 1,184 | $58.92 | $69.8K | 115,466 | SEC↗ |
| CAREY STEPHEN P. | SVP & CFO | F Tax w/h | 2025-02-14 | 2025-02-18 | 1,730 | $58.92 | $101.9K | 194,084 | SEC↗ |
| Cook Meredith | SR. VP, GENERAL COUNSEL & SE | F Tax w/h | 2025-02-14 | 2025-02-18 | 1,434 | $58.92 | $84.5K | 82,044 | SEC↗ |
| Davis Krista | SVP, CHIEF HR OFFICER | F Tax w/h | 2025-02-14 | 2025-02-18 | 1,196 | $58.92 | $70.5K | 69,624 | SEC↗ |
| Gutwerg Ori | SVP, GENERICS | F Tax w/h | 2025-02-14 | 2025-02-18 | 1,426 | $58.92 | $84.0K | 101,913 | SEC↗ |
| Lalwani Nikhil | PRESIDENT & CEO | F Tax w/h | 2025-02-14 | 2025-02-18 | 7,799 | $58.92 | $459.5K | 514,910 | SEC↗ |
| Mutz Christopher | HEAD OF RARE DISEASE | F Tax w/h | 2025-02-14 | 2025-02-18 | 1,473 | $58.92 | $86.8K | 116,650 | SEC↗ |
| Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRAN | F Tax w/h | 2025-02-14 | 2025-02-18 | 582 | $58.92 | $34.3K | 46,092 | SEC↗ |
| Cook Meredith | SR. VP, GENERAL COUNSEL & SE | S Sale | 2025-02-13 | 2025-02-18 | 400 | $59.54 | $23.8K | 83,478 | SEC↗ |
| CAREY STEPHEN P. | SVP & CFO | A Award | 2025-02-12 | 2025-02-18 | 16,538 | — | $0 | 195,814 | SEC↗ |
| CAREY STEPHEN P. | SVP & CFO | A Award | 2025-02-12 | 2025-02-18 | 24,808 | — | $0 | 179,276 | SEC↗ |
| Cook Meredith | SR. VP, GENERAL COUNSEL & SE | A Award | 2025-02-12 | 2025-02-18 | 11,316 | — | $0 | 83,878 | SEC↗ |
| Cook Meredith | SR. VP, GENERAL COUNSEL & SE | A Award | 2025-02-12 | 2025-02-18 | 16,974 | — | $0 | 72,562 | SEC↗ |
| Davis Krista | SVP, CHIEF HR OFFICER | A Award | 2025-02-12 | 2025-02-18 | 8,704 | — | $0 | 70,820 | SEC↗ |
| Davis Krista | SVP, CHIEF HR OFFICER | A Award | 2025-02-12 | 2025-02-18 | 13,057 | — | $0 | 62,116 | SEC↗ |
| Gassert Chad | SVP - CORP. DEV. & STRATEGY | A Award | 2025-02-12 | 2025-02-18 | 14,362 | — | $0 | 64,041 | SEC↗ |
| Gassert Chad | SVP - CORP. DEV. & STRATEGY | A Award | 2025-02-12 | 2025-02-18 | 9,574 | — | $0 | 73,615 | SEC↗ |
| Gutwerg Ori | SVP, GENERICS | A Award | 2025-02-12 | 2025-02-18 | 10,444 | — | $0 | 103,339 | SEC↗ |
| Gutwerg Ori | SVP, GENERICS | A Award | 2025-02-12 | 2025-02-18 | 15,668 | — | $0 | 92,895 | SEC↗ |
| Lalwani Nikhil | PRESIDENT & CEO | A Award | 2025-02-12 | 2025-02-18 | 60,932 | — | $0 | 522,709 | SEC↗ |
| Lalwani Nikhil | PRESIDENT & CEO | A Award | 2025-02-12 | 2025-02-18 | 91,399 | — | $0 | 461,777 | SEC↗ |
| Mutz Christopher | HEAD OF RARE DISEASE | A Award | 2025-02-12 | 2025-02-18 | 16,538 | — | $0 | 118,123 | SEC↗ |
| Mutz Christopher | HEAD OF RARE DISEASE | A Award | 2025-02-12 | 2025-02-18 | 24,808 | — | $0 | 101,585 | SEC↗ |
| Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRAN | A Award | 2025-02-12 | 2025-02-18 | 7,834 | — | $0 | 41,452 | SEC↗ |
| Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRAN | A Award | 2025-02-12 | 2025-02-18 | 5,222 | — | $0 | 46,674 | SEC↗ |
| Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OP | A Award | 2025-02-12 | 2025-02-18 | 9,574 | — | $0 | 92,588 | SEC↗ |
| Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OP | A Award | 2025-02-12 | 2025-02-18 | 14,362 | — | $0 | 83,014 | SEC↗ |
| Cook Meredith | SR. VP, GENERAL COUNSEL & SE | S Sale | 2025-01-13 | 2025-01-13 | 400 | $53.92 | $21.6K | 55,588 | SEC↗ |
| CAREY STEPHEN P. | SVP & CFO | S Sale | 2024-12-17 | 2024-12-18 | 7,500 | $55.79 | $418.4K | 154,468 | SEC↗ |
| Cook Meredith | SR. VP, GENERAL COUNSEL & SE | S Sale | 2024-12-13 | 2024-12-16 | 250 | $56.24 | $14.1K | 55,988 | SEC↗ |
| Davis Krista | SVP, CHIEF HR OFFICER | S Sale | 2024-12-11 | 2024-12-12 | 1,000 | $60.00 | $60.0K | 49,059 | SEC↗ |
| Lalwani Nikhil | PRESIDENT & CEO | M Exercise deriv | 2024-11-26 | 2024-11-27 | 30,000 | $29.00 | $870.0K | 138,027 | SEC↗ |
| Lalwani Nikhil | PRESIDENT & CEO | S Sale | 2024-11-26 | 2024-11-27 | 3,481 | $58.30 | $202.9K | 370,378 | SEC↗ |
| Lalwani Nikhil | PRESIDENT & CEO | M Exercise | 2024-11-26 | 2024-11-27 | 30,000 | $29.00 | $870.0K | 403,859 | SEC↗ |
| Lalwani Nikhil | PRESIDENT & CEO | S Sale | 2024-11-26 | 2024-11-27 | 30,000 | $57.95 | $1.74M | 373,859 | SEC↗ |
| Mutz Christopher | HEAD OF RARE DISEASE | S Sale | 2024-11-15 | 2024-11-18 | 6,500 | $57.70 | $375.1K | 76,777 | SEC↗ |
| Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRAN | F Tax w/h | 2024-11-15 | 2024-11-18 | 867 | $56.58 | $49.1K | 33,169 | SEC↗ |
| Cook Meredith | SR. VP, GENERAL COUNSEL & SE | S Sale | 2024-11-13 | 2024-11-14 | 250 | $61.36 | $15.3K | 56,238 | SEC↗ |
| Cook Meredith | SR. VP, GENERAL COUNSEL & SE | S Sale | 2024-10-14 | 2024-10-15 | 250 | $57.19 | $14.3K | 56,488 | SEC↗ |
| Cook Meredith | SR. VP, GENERAL COUNSEL & SE | S Sale | 2024-09-13 | 2024-09-16 | 250 | $56.82 | $14.2K | 56,738 | SEC↗ |
| Davis Krista | SVP, CHIEF HR OFFICER | F Tax w/h | 2024-09-12 | 2024-09-13 | 1,486 | $56.15 | $83.4K | 50,059 | SEC↗ |
| Lalwani Nikhil | PRESIDENT & CEO | F Tax w/h | 2024-09-08 | 2024-09-10 | 3,646 | $60.51 | $220.6K | 373,859 | SEC↗ |
| Cook Meredith | SR. VP, GENERAL COUNSEL & SE | S Sale | 2024-08-13 | 2024-08-14 | 250 | $59.62 | $14.9K | 56,988 | SEC↗ |
| Cook Meredith | SR. VP, GENERAL COUNSEL & SE | F Tax w/h | 2024-07-18 | 2024-07-19 | 1,743 | $61.35 | $106.9K | 57,238 | SEC↗ |
| Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OP | S Sale | 2024-07-18 | 2024-07-19 | 2,743 | $62.00 | $170.1K | 632,620 | SEC↗ |
| Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OP | S Sale | 2024-07-17 | 2024-07-17 | 14,257 | $63.16 | $900.5K | 635,363 | SEC↗ |
| Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OP | S Sale | 2024-07-16 | 2024-07-17 | 22,000 | $64.27 | $1.41M | 649,620 | SEC↗ |
| Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OP | S Sale | 2024-07-15 | 2024-07-17 | 11,000 | $63.38 | $697.2K | 671,620 | SEC↗ |
| Cook Meredith | SR. VP, GENERAL COUNSEL & SE | S Sale | 2024-07-12 | 2024-07-15 | 250 | $64.91 | $16.2K | 58,981 | SEC↗ |
| Gassert Chad | SVP - CORP. DEV. & STRATEGY | S Sale | 2024-07-01 | 2024-07-02 | 20,000 | $63.44 | $1.27M | 193,226 | SEC↗ |
| Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OP | S Sale | 2024-06-21 | 2024-06-24 | 20,000 | $58.90 | $1.18M | 682,620 | SEC↗ |
| Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OP | S Sale | 2024-06-20 | 2024-06-20 | 11,447 | $59.86 | $685.2K | 702,620 | SEC↗ |
| Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OP | S Sale | 2024-06-18 | 2024-06-20 | 10,607 | $60.76 | $644.5K | 714,067 | SEC↗ |
| Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OP | S Sale | 2024-06-17 | 2024-06-20 | 7,946 | $61.41 | $488.0K | 724,674 | SEC↗ |
| Cook Meredith | SR. VP, GENERAL COUNSEL & SE | S Sale | 2024-06-13 | 2024-06-14 | 250 | $63.80 | $15.9K | 59,231 | SEC↗ |
| Marken James G. | SVP OPS & PROD DEV | M Exercise deriv | 2024-06-07 | 2024-06-11 | 7,250 | $49.51 | $358.9K | 0 | SEC↗ |
| Marken James G. | SVP OPS & PROD DEV | M Exercise deriv | 2024-06-07 | 2024-06-11 | 5,300 | $57.06 | $302.4K | 0 | SEC↗ |
| Marken James G. | SVP OPS & PROD DEV | F Tax w/h | 2024-06-07 | 2024-06-11 | 11,087 | $67.70 | $750.6K | 117,829 | SEC↗ |
| Marken James G. | SVP OPS & PROD DEV | M Exercise | 2024-06-07 | 2024-06-11 | 7,250 | $49.51 | $358.9K | 123,616 | SEC↗ |
| Marken James G. | SVP OPS & PROD DEV | M Exercise | 2024-06-07 | 2024-06-11 | 5,300 | $57.06 | $302.4K | 128,916 | SEC↗ |
| Gutwerg Ori | SVP, GENERICS | S Sale | 2024-06-05 | 2024-06-06 | 2,985 | $67.00 | $200.0K | 77,227 | SEC↗ |
| CAREY STEPHEN P. | SVP & CFO | S Sale | 2024-06-04 | 2024-06-06 | 5,000 | $63.58 | $317.9K | 161,968 | SEC↗ |
| Gassert Chad | SVP - CORP. DEV. & STRATEGY | S Sale | 2024-06-03 | 2024-06-04 | 20,000 | $64.41 | $1.29M | 213,226 | SEC↗ |
| Mutz Christopher | HEAD OF RARE DISEASE | S Sale | 2024-05-21 | 2024-05-22 | 2,000 | $61.61 | $123.2K | 83,277 | SEC↗ |
| HAUGHEY THOMAS | Director | A Award | 2024-05-21 | 2024-05-23 | 4,410 | — | $0 | 51,526 | SEC↗ |
| Leonard Matthew J | Director | A Award | 2024-05-21 | 2024-05-23 | 4,410 | — | $0 | 11,993 | SEC↗ |
| Pera Antonio R | Director | A Award | 2024-05-21 | 2024-05-23 | 4,410 | — | $0 | 31,037 | SEC↗ |
| TANNENBAUM RENEE P | Director | A Award | 2024-05-21 | 2024-05-23 | 4,410 | — | $0 | 22,621 | SEC↗ |
| Thoma Jeanne | Director | A Award | 2024-05-21 | 2024-05-23 | 4,410 | — | $0 | 40,609 | SEC↗ |
| Walsh Patrick D | Director | A Award | 2024-05-21 | 2024-05-23 | 4,410 | — | $0 | 74,712 | SEC↗ |
| Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OP | S Sale | 2024-05-20 | 2024-05-21 | 12,855 | $61.81 | $794.6K | 732,620 | SEC↗ |
| Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OP | S Sale | 2024-05-17 | 2024-05-17 | 5,836 | $62.09 | $362.4K | 745,475 | SEC↗ |
| TANNENBAUM RENEE P | Director | S Sale | 2024-05-16 | 2024-05-17 | 2,000 | $63.87 | $127.7K | 18,211 | SEC↗ |
| Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OP | S Sale | 2024-05-16 | 2024-05-17 | 16,459 | $63.84 | $1.05M | 751,311 | SEC↗ |
| Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OP | S Sale | 2024-05-15 | 2024-05-17 | 14,850 | $65.86 | $978.0K | 767,770 | SEC↗ |
| Lalwani Nikhil | PRESIDENT & CEO | S Sale | 2024-05-14 | 2024-05-16 | 16,669 | $66.10 | $1.10M | 377,505 | SEC↗ |
| Cook Meredith | SR. VP, GENERAL COUNSEL & SE | S Sale | 2024-05-13 | 2024-05-13 | 250 | $67.69 | $16.9K | 59,481 | SEC↗ |
| Gassert Chad | SVP - CORP. DEV. & STRATEGY | S Sale | 2024-05-01 | 2024-05-03 | 20,000 | $66.62 | $1.33M | 233,226 | SEC↗ |
| Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OP | S Sale | 2024-04-19 | 2024-04-22 | 16,809 | $65.17 | $1.10M | 782,620 | SEC↗ |
| Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OP | S Sale | 2024-04-18 | 2024-04-22 | 10,423 | $64.98 | $677.3K | 799,429 | SEC↗ |
| Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OP | S Sale | 2024-04-17 | 2024-04-17 | 9,520 | $65.40 | $622.6K | 809,852 | SEC↗ |
| Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OP | S Sale | 2024-04-16 | 2024-04-17 | 5,834 | $66.20 | $386.2K | 819,372 | SEC↗ |
| Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OP | S Sale | 2024-04-15 | 2024-04-17 | 7,414 | $66.33 | $491.8K | 825,206 | SEC↗ |
| Cook Meredith | SR. VP, GENERAL COUNSEL & SE | S Sale | 2024-04-12 | 2024-04-15 | 250 | $67.79 | $16.9K | 59,731 | SEC↗ |
| CAREY STEPHEN P. | SVP & CFO | F Tax w/h | 2024-04-10 | 2024-04-11 | 4,534 | $66.96 | $303.6K | 166,968 | SEC↗ |
| Marken James G. | SVP OPS & PROD DEV | F Tax w/h | 2024-04-10 | 2024-04-11 | 2,799 | $66.96 | $187.4K | 116,006 | SEC↗ |
| Gassert Chad | SVP - CORP. DEV. & STRATEGY | S Sale | 2024-04-01 | 2024-04-02 | 20,000 | $67.25 | $1.34M | 253,226 | SEC↗ |
| Lalwani Nikhil | PRESIDENT & CEO | F Tax w/h | 2024-03-23 | 2024-03-25 | 17,455 | $69.58 | $1.21M | 394,174 | SEC↗ |
| Marken James G. | SVP OPS & PROD DEV | F Tax w/h | 2024-03-23 | 2024-03-25 | 3,653 | $69.58 | $254.2K | 118,805 | SEC↗ |
| CAREY STEPHEN P. | SVP & CFO | F Tax w/h | 2024-03-23 | 2024-03-25 | 6,210 | $69.58 | $432.1K | 171,502 | SEC↗ |
| Cook Meredith | SR. VP, GENERAL COUNSEL & SE | S Sale | 2024-03-13 | 2024-03-13 | 250 | $66.54 | $16.6K | 59,981 | SEC↗ |
| CAREY STEPHEN P. | SVP & CFO | S Sale | 2024-03-11 | 2024-03-11 | 7,787 | $65.55 | $510.4K | 177,712 | SEC↗ |
| Gassert Chad | SVP - CORP. DEV. & STRATEGY | S Sale | 2024-03-11 | 2024-03-13 | 20,000 | $65.81 | $1.32M | 273,226 | SEC↗ |
| Lalwani Nikhil | PRESIDENT & CEO | S Sale | 2024-03-08 | 2024-03-08 | 16,292 | $67.13 | $1.09M | 411,629 | SEC↗ |
| Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OP | S Sale | 2024-03-08 | 2024-03-11 | 10,000 | $67.17 | $671.7K | 832,620 | SEC↗ |
| Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OP | S Sale | 2024-03-07 | 2024-03-07 | 15,085 | $66.35 | $1.00M | 842,620 | SEC↗ |
| Mutz Christopher | HEAD OF RARE DISEASE | F Tax w/h | 2024-03-07 | 2024-03-07 | 2,110 | $66.71 | $140.8K | 85,277 | SEC↗ |
| Gutwerg Ori | SVP, GENERICS | F Tax w/h | 2024-03-07 | 2024-03-07 | 2,494 | $66.71 | $166.4K | 80,212 | SEC↗ |
| Marken James G. | SVP OPS & PROD DEV | F Tax w/h | 2024-03-07 | 2024-03-07 | 2,034 | $66.71 | $135.7K | 122,458 | SEC↗ |
| Marken James G. | SVP OPS & PROD DEV | S Sale | 2024-03-07 | 2024-03-07 | 24,338 | $66.37 | $1.62M | 124,492 | SEC↗ |
| Lalwani Nikhil | PRESIDENT & CEO | F Tax w/h | 2024-03-07 | 2024-03-08 | 17,060 | $66.71 | $1.14M | 427,921 | SEC↗ |
| CAREY STEPHEN P. | SVP & CFO | F Tax w/h | 2024-03-07 | 2024-03-11 | 4,216 | $66.71 | $281.2K | 185,499 | SEC↗ |
| Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OP | S Sale | 2024-03-06 | 2024-03-07 | 14,822 | $65.47 | $970.4K | 857,705 | SEC↗ |
| Lalwani Nikhil | PRESIDENT & CEO | S Sale | 2024-03-06 | 2024-03-08 | 28,965 | $65.52 | $1.90M | 444,981 | SEC↗ |
| Mutz Christopher | HEAD OF RARE DISEASE | S Sale | 2024-03-05 | 2024-03-06 | 5,000 | $66.00 | $330.0K | 87,387 | SEC↗ |
| Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OP | S Sale | 2024-03-05 | 2024-03-07 | 10,093 | $65.35 | $659.6K | 872,527 | SEC↗ |
| Pera Antonio R | Director | S Sale | 2024-03-04 | 2024-03-06 | 7,000 | $65.20 | $456.4K | 26,627 | SEC↗ |
| CAREY STEPHEN P. | SVP & CFO | F Tax w/h | 2024-02-29 | 2024-03-01 | 1,914 | $67.67 | $129.5K | 189,715 | SEC↗ |
| Cook Meredith | SR. VP, GENERAL COUNSEL & SE | F Tax w/h | 2024-02-29 | 2024-03-01 | 1,173 | $67.67 | $79.4K | 60,231 | SEC↗ |
| Davis Krista | SVP, CHIEF HR OFFICER | F Tax w/h | 2024-02-29 | 2024-03-01 | 1,173 | $67.67 | $79.4K | 51,545 | SEC↗ |
| Gassert Chad | SVP - CORP. DEV. & STRATEGY | F Tax w/h | 2024-02-29 | 2024-03-01 | 1,635 | $67.67 | $110.6K | 49,679 | SEC↗ |
| Gutwerg Ori | SVP, GENERICS | F Tax w/h | 2024-02-29 | 2024-03-01 | 1,570 | $67.67 | $106.2K | 82,706 | SEC↗ |
| Lalwani Nikhil | PRESIDENT & CEO | F Tax w/h | 2024-02-29 | 2024-03-01 | 10,014 | $67.67 | $677.6K | 473,946 | SEC↗ |
| Marken James G. | SVP OPS & PROD DEV | F Tax w/h | 2024-02-29 | 2024-03-01 | 1,058 | $67.67 | $71.6K | 148,830 | SEC↗ |
| Mutz Christopher | HEAD OF RARE DISEASE | F Tax w/h | 2024-02-29 | 2024-03-01 | 1,275 | $67.67 | $86.3K | 92,387 | SEC↗ |
| Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OP | F Tax w/h | 2024-02-29 | 2024-03-01 | 1,122 | $67.67 | $75.9K | 68,652 | SEC↗ |
| Mutz Christopher | HEAD OF RARE DISEASE | F Tax w/h | 2024-02-15 | 2024-02-20 | 1,261 | $57.55 | $72.6K | 93,662 | SEC↗ |
| Gutwerg Ori | SVP, GENERICS | F Tax w/h | 2024-02-15 | 2024-02-20 | 1,244 | $57.55 | $71.6K | 84,276 | SEC↗ |
| CAREY STEPHEN P. | SVP & CFO | A Award | 2024-02-14 | 2024-02-16 | 21,474 | — | $0 | 177,313 | SEC↗ |